- Home
- ALGS
as 11-15-2024 4:00pm EST
Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 23.5M | IPO Year: | 2020 |
| Target Price: | $75.00 | AVG Volume (30 days): | 476.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -12.89 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.76 - $30.00 | Next Earning Date: | 11-06-2024 |
| Revenue: | $5,997,000 | Revenue Growth: | -63.40% |
| Revenue Growth (this year): | -78.18% | Revenue Growth (next year): | -59.87% |
Latest Aligos Therapeutics Inc. News
ALGS Breaking Stock News: Dive into ALGS Ticker-Specific Updates for Smart Investing
Simply Wall St.
7 days ago
Aligos Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations
Zacks
11 days ago
Aligos Therapeutics, Inc. (ALGS) Reports Q3 Loss, Tops Revenue Estimates
GlobeNewswire
11 days ago
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results
GlobeNewswire
18 days ago
Aligos Therapeutics to Announce 3rd Quarter 2024 Financial Results on November 6, 2024
GlobeNewswire
a month ago
Aligos Therapeutics Announces U.S. FDA Clearance of IND Application for ALG-000184
GlobeNewswire
a month ago
Aligos Therapeutics Announces Acceptance of Abstracts on Incremental Data from ALG-000184 in CHB Subjects and Late-Breaker Oral Presentation of Data from the Phase 2a HERALD Study of ALG-055009 in MASH Subjects at The Liver Meeting (TLM) 2024
GlobeNewswire
a month ago
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
2 months ago
Aligos Therapeutics Appoints David Perry as Vice President of Business Development
Compare ALGS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ALGS Aligos Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.